AlphaQuest LLC Sells 10,498 Shares of Zoetis Inc. $ZTS

AlphaQuest LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 78.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,909 shares of the company’s stock after selling 10,498 shares during the quarter. AlphaQuest LLC’s holdings in Zoetis were worth $454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of ZTS. Brighton Jones LLC increased its stake in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Alta Advisers Ltd grew its position in Zoetis by 59.1% during the 1st quarter. Alta Advisers Ltd now owns 2,423 shares of the company’s stock valued at $399,000 after purchasing an additional 900 shares during the last quarter. Mather Group LLC. grew its position in Zoetis by 4.4% during the 1st quarter. Mather Group LLC. now owns 3,549 shares of the company’s stock valued at $584,000 after purchasing an additional 151 shares during the last quarter. Rossby Financial LCC grew its position in Zoetis by 22.6% during the 1st quarter. Rossby Financial LCC now owns 4,459 shares of the company’s stock valued at $684,000 after purchasing an additional 822 shares during the last quarter. Finally, Arbor Capital Management Inc. ADV grew its position in Zoetis by 5.7% during the 1st quarter. Arbor Capital Management Inc. ADV now owns 6,137 shares of the company’s stock valued at $1,002,000 after purchasing an additional 331 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $143.97 on Thursday. The firm’s 50-day moving average price is $147.63 and its 200-day moving average price is $153.48. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market cap of $63.80 billion, a PE ratio of 24.78, a PEG ratio of 2.34 and a beta of 0.90. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $183.81.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is presently 34.42%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. UBS Group cut their price objective on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday, October 20th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.